# Efficacy and Safety of Exenatide Once Weekly Suspension in Subjects With Type 2 Diabetes

Study · id `cardio:ct-nct01652716` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01652716](<https://clinicaltrials.gov/study/NCT01652716>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01652716

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 377 participants.

## Technical summary

Registry record NCT01652716. Randomized; no masking; primary purpose treatment. Start 2013-01 (registry gives no type); primary completion 2014-08 (actual). Results posted on 2015-09-16.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 377 participants (enrolled count; ClinicalTrials.gov record NCT01652716, source copy `cardio:ctgov-nct01652716-2018-07-03`, retrieved 2026-10-26)
- Start date: 2013-01 (registry gives no type) (ClinicalTrials.gov record NCT01652716, source copy `cardio:ctgov-nct01652716-2018-07-03`, retrieved 2026-10-26)
- Primary completion: 2014-08 (actual) (ClinicalTrials.gov record NCT01652716, source copy `cardio:ctgov-nct01652716-2018-07-03`, retrieved 2026-10-26)
- Completion: 2014-08 (actual) (ClinicalTrials.gov record NCT01652716, source copy `cardio:ctgov-nct01652716-2018-07-03`, retrieved 2026-10-26)
- Results first posted: 2015-09-16 (ClinicalTrials.gov record NCT01652716, source copy `cardio:ctgov-nct01652716-2018-07-03`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT01652716, source copy `cardio:ctgov-nct01652716-2018-07-03`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01652716-2018-07-03`, retrieved 2026-10-26)

## The registry's words

- Brief title: Efficacy and Safety of Exenatide Once Weekly Suspension in Subjects With Type 2 Diabetes
- Acronym: DURATION-NEO-1
- Condition: Diabetes Mellitus, Type 2
- Intervention (Drug): Exenatide once weekly suspension
- Intervention (Drug): Exenatide twice daily
- Lead sponsor: AstraZeneca
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: AstraZeneca (`cardio:astrazeneca`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Efficacy and tolerability of the new autoinjected suspension of exenatide once weekly versus exenatide twice daily in patients with type 2 diabetes (`cardio:pubmed-28685973`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Further improvement in glycemic control after switching from exenatide two times per day to exenatide once-weekly autoinjected suspension in patients with type 2 diabetes: 52-week results from the DURATION-NEO-1 study (`cardio:pubmed-33037036`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 9d1b52884fc0cb726a6746f1a3bcbd97a2a30aca430acc9d54a26e39f0a0bbc7
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
